


Cancer Molecular Pathology and Therapeutic Targets Group

Publications: 23
Q1: 9



RESEARCH ACTIVITY


Publications

- Ahmad H, Vilanova-Sánchez A, Amengual I, Guerra-Pastrián L, Garrido-Pontnou M, Montalvo C, Bueno A, Langer J, Woods RJ, Levitt MA. Skip segment hirschsprung disease managed by pull-through of the right colon. *European J Pediatr Surg Rep.* 2021; 9(1): E28-32. Article. Not Indexed
- Andrés AM, Stringa P, Talayero P, Santamaria M, García-Arranz M, Gómez-Heras SG, Largo-


- Aramburu C, Aras-López RM, Vallejo-Cremades MT, Pastrián LG, Vega L, Encinas JL, López-Santamaria M, Hernández-Oliveros F. Graft infusion of adipose-derived mesenchymal stromal cells to prevent rejection in experimental intestinal transplantation: A feasibility study. *Clin Transplant.* 2021; 35(4): e14226. Article. IF: 3.456; Q2
- Dajti I, Valenzuela JI, Boccalatte LA, Gemelli NA, Smith DE, Dudi-Venkata NN, Kroon HM, Sammour T, Roberts M, Mitchell D, Lah K, Pearce A, Carrasco-Prats M, Gimenez-Francois

- C, Ruiz-Marin M, Fernández-López AJ (et al). Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score. *Brit J Surg.* 2021; 108(11): 1274-92. Article. IF: 11.122; D1
- Diestro MD, Berjón A, Zapardiel I, Yébenes L, Ruiz I, Lekuona A, Rezola M, Jaunarena I, Siegrist J, Sánchez-Pastor M, Cuadra M, Sagasta A, Guerra I, Lete LI, Roldán F, Marta CB, Boillos M, Cardiel M, López-de la Manzanara C, Relea F,

- Coronado P, Pascual A, Román M, Peiro G, Matute L, Montero B, Muruzabal J, Guarch R, Zorrero C, Calatrava A, Ribot L, Costa I, Hernández A, Hardisson D. One-step nucleic acid amplification (osna) of sentinel lymph node in early-stage endometrial cancer: spanish multicenter study (ENDO-OSNA). *Cancers (Basel).* 2021; 13(17): 4465. Article. IF: 6.575; Q2
- Escudero A, Ruz-Caracul B, Bueno D, Martínez M, Rubio P, Regojo RM, Antolin E, Ybarra M, Martínez L, Pozo-Kreiling JJ, Elorza MD, Pe-



- llicer A, Omeñaca F, Pérez-Martínez A. Genetic predisposition to fetal and neonatal cancer. *Clin Transl Oncol.* 2021; 23(6): 1179-84. Article. IF: 3.34; Q3
- Escudero J, Heredia-Soto V, Wang YY, Ruiz P, Hu YY, Gallego A, Pozo-Kreiling JJ, Martínez-Maín V, Berjón A, Ortiz-Cruz E, Bernabéu D, Feliú J, Tang J, Redondo A, Mendiola M. Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect? *Cancer Cell Int.* 2021; 21(1): 646. Article. IF: 6.436; Q2
 - Fernández-Acenero MJ, Barderas R, García AP, Martínez-Useros J, Díez-Valladares L, Pérez-Aguirre, Medina LO, Esteban SD, García-Botella S, del Arco CD, Galindo C. Aryl hydrocarbon receptor interacting protein (AIP) significantly influences prognosis of pancreatic carcinoma. *Ann Diagn Pathol.* 2021;



53: 151742. Article. IF: 2.134; Q3

- Gallego A, Garrido D, Yébenes L, Mendiola M, Castelo B, Redondo A. Long-term response to olaparib in BRCA1-related ovarian cancer with brain metastases. *Int J Gynecol Cancer.* 2021; 31(9): 1292-6. Article. IF: 4.661; Q1
- Gil-Moreno A, Alonso-Alconada L, Díaz-Feijoo B, Domingo S, Vilar A, Hernández A, Gilabert J, Lluca A, Torne A, de Santiago J, Carbonell-Socias M, Lago V, Arias E, Sampayo V, Siegrist J, Chipirliu A, Sánchez-Iglesias JL, Pérez-Benavente A, Padilla-Iserte P, Santacana M, Matias-Guiu X, Abal M, López-López R. M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients. *Gynecol Oncol.* 2021; 161(3): 681-6. Article. IF: 5.304; Q1
- Glasbey JC, Omar O, Nepogodiev D, Minaya-Bravo A, Bankhead-Kendall BK, Fiore M, Futaba K, Gabre-Kidan A, Gujjuri RR, Isik A, Kaafarani HMA, (et al) Lamb B, Liao S, Luke L. Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic. *Brit J Surg.* 2021; 108(1): 88-96. Article. IF: 11.122; D1
- López-Janeiro A, Ruz-Caracuel I, Ramón-Patino JL, de los Ríos V, Esparza MV, Berjón A, Yébenes L, Hernández A, Massetto I, Kadioglu E, Goubert V, Heredia-Soto V, Barderas R, Casal JI, de Andrea CE, Redondo A, Mendiola M, Pelaez-García A, Hardisson D. Proteomic analysis of low-grade, early-stage endometrial carcinoma reveals new dysregulated pathways associated with cell death and cell signaling. *Cancers (Basel).* 2021; 13(4): 794. Article. IF: 6.575; Q2
- Marti C, Sánchez-

Méndez JI. The present and future of neoadjuvant endocrine therapy for breast cancer treatment. *Cancers (Basel).* 2021; 13(11): 2538. Review. IF: 6.575; Q2

- Mayoral-Varo V, Sánchez-Bailón MP, Calcabrini A, García-Hernández M, Frezza V, Martín ME, González VM, Martín-Pérez J. The Relevance of the SH2 domain for c-src functionality in triple-negative breast cancer cells. *Cancers (Basel).* 2021; 13(3): 462. Article. IF: 6.575; Q2
- Povedano E, Gamella M, Torrente-Rodríguez RM, Montiel VRV, Montero-Calle A, Solís-Fernández G, Navarro-Villoslada F, Peláez-García A, Mendiola M, Hardisson D, Feliú J, Barderas R, Pingarrón JM, Campuzano S. Multiplexed magnetic beads-assisted amperometric bioplatforams for global detection of methylations in nucleic acids. *Anal Chim Acta.* 2021; 1182: 338946. Article. IF: 6.911; Q1
- Rodríguez-Antolín C, Rosas-Alonso R, Cruz P, Higuera O, Sánchez-Cabrero D, Esteban-Rodríguez I, Peláez-García A, Montano VEF, Rodríguez-Jiménez C, de Caceres II, de Castro J. Novel SLC12A2-ROS1 fusion in non-small cell lung cancer with a significant response to crizotinib: the importance of choosing the appropriate next-generation sequencing assay. *Oncologist.* 2021; 26(6): E908-12. Article. IF: 5.837; Q2
- Roig CA, Cordon JP, Gallego MA, Pastrían LG. Ileal endometriosis in a patient with Crohn's disease: a diagnostic challenge. *Rev Esp Enferm Dig.* 2021; 113(12): 847. Letter. IF: 2.389; Q4
- Ruz-Caracuel I, López-Janeiro A, Heredia-Soto V, Ramón-Patino JL, Yébenes L, Berjón A, Hernández A, Gallego A, Ruiz P, Redondo A, Peláez-García A, Mendiola M, Hardisson D. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma. *Virchows Arch.* 2021; 479(6): 1167-76. Article. IF: 4.535; Q2
- San Segundo-Acosta P, Montero-Calle A, Jernbom-Falk A, Alonso-Navarro M, Pin E, Andersson E, Hellstrom C, Sánchez-Martínez M, Rabano A, Solís-Fernández G, Peláez-García A, Martínez-Useros J, Fernández-Acenero MJ, Manberg A, Nilsson P, Barderas R. Multiomics profiling of alzheimer's disease serum for the identification of autoantibody biomarkers. *J Proteome Res.* 2021; 20(11): 5115-30. Article. IF: 5.37; Q1
- Sánchez MDC, Gómez VG, Urgelles AS, de Sábando DPL, Aparicio PR, Martínez LM, Gamarra EA, Kreilinger JJP, Zapata RMR, Gutiérrez JCL, Alvarado EA, Martín FG, Torres AMS, Manzano


EM, del Valle LG, Pérez-Martínez A. Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report. *Pediatr Hemat Oncol.* 2021; 38(5): 504-9. Article. IF: 2.07; Q3

- Tabiri S, Kamarajah SK, Nepogodiev D, Li E, Simoes J, Sravanam S, Owusu SA, Mahama H, Agyeman YN, Arthur J, Kunfah SM, Fernández-Candela A, Curtis-Martínez C, Soler-Silva A, Oller A, Triguero-Canovas D, Bosch-Ramírez M, Lillo C, Lario S, Arroyo A, Segura-Illa ME, Aniceto GS, Castano-Leon AM, Jiménez-Roldan L, Fernández JD (et al). Impact of Bacillus Calmette-Guerin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection. *BJS Open.* 2021; 5(6): zrab131. Letter. IF: 3.875; Q1
- Trilla-Fuentes L, Gámez-Pozo A, Maurel J, García-Carbonero R, Capdevila J, G-Pastrian L, Mendiola M, Pena C, López-Vacas R, Cuatrecasas M, García-Alfonso P, Ramos-Ruiz R, Llorens C, Ghanem I, Conill C, Heredia-Soto V, Campos-Barros A, Vara JAF, Feliú J. Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab. *Sci Rep-Uk.* 2021; 11(1): 7402. Article. IF: 4.996; Q2
- Zapardiel I, Boria F, Halaska MJ, de Santiago J. Laparoscopic power morcellation: techniques to avoid tumoral spread. *J Minim Invas Gyn.* 2021; 28(8): 1442-3. Editorial Material. IF: 4.314; Q1
- Zapardiel I, Kocian R, Kohler C, Klat J, Germanova A, Jacob A, Bajsova S, Bohmer G, Lay L, Gil-Ibanez B, Havelka P, Kipp B, Szweczyk G, Toth R, Staringer JC, de Santiago J, Coronado PJ, Poka R, Laky R, Luyckx M, Fastrez M, Dusek L, Hernández A, Cibula D. Voiding recovery after radical parametrectomy in cervical cancer patients: An international prospective multicentre trial - SENTIX. *Gynecol Oncol.* 2021; 160(3): 729-34. Article. IF: 5.304; Q1

Research projects

Guerra Pastrían L. Desarrollo de tareas de revisión patológica nacional del ensayo clínico Paediatric Hepatic International Tumour Trial (PHITT). Fundación para la Investigación Biomédica de Córdoba Fíbico. 2019-Ongoing.

Managment centre: FIBHULP



Hardisson Hernández D. Aplicabilidad de la proteogenómica en la progresión del carcinoma endometrioide de endometrio diagnosticado en estadios iniciales (PI17/01723). ISCIII. 2018-2021.

Managment centre: FIBHULP

Hardisson Hernández D. Riesgo de recaída en pacientes con carcinoma de mama primario HER2 negativo y receptores estrogénicos positivos: estudio comparativo de dos perfiles de expresión génica (Mammaprint® y Endopredict®). Fundación Sociedad Española de Anatomía Patológica. 2019-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M. Hardisson Hernández D. Identificación de biomarcadores en cáncer de pulmón no microcítico. AstraZeneca Farmacéutica Spain S. A. 2020-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M. Exploration of 2 and 3d models of angiosarcoma and their farcological sdreening. Grupo Español de Investigación en Sarcomas. 2019-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M. Identificación de perfiles de expresión génica diferencial relacionados con la angiogénesis entre el carcinoma de ovario primario y sus metástasis. Ortomedimatec. 2012-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M. Papel de RANKL en el sarcoma de Ewing: un estudio in vitro para la confirmación de una nueva diana terapéutica. Grupo Español de Investigación en Sarcomas. 2012-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M. Realización de técnicas de detección de expresión proteica el IGTP. Construcción de matrices tisulares y tinciones con anticuerpos específicos. Fundacio Institut D'investigació en Ciències de la S. A.lut Germans Trias I Pujol. 2015-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M. Identificación de marcadores de HRD y predicción de la respuesta a inhibidores dePARP en líneas celulares establecidas y organoides derivados de pacientes con cancer de ovario. Grupo Español de Investigación Cancer de Ovario (GEICO). 2021-Ongoing.

Managment centre: FIBHULP

■ Patents and trademarks

Redondo Sánchez A, Hardisson Hernández D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Hernández D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.